SAN FRANCISCO — Coronary Event Risk Test (CERT), a new validated cardiovascular (CV) risk predictor based on circulating ceramide concentrations, can predict CV mortality in patients with preexisting CV disease, with and without type 2 diabetes (T2D), according to study results presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019.
The researchers investigated the use of CERT to predict CV mortality in patients with established CV disease. The study enrolled 1087 patients, including 360 patients with T2D. According to CERT, patients were classified into 1 of 4 risk categories based on ceramide concentration; T2D was more common throughout the risk categories (29.1% in category I, 31.1% in category II, 37.4% in category III, and 53.4% in category IV; P <.001).
During mean follow-up of approximately 8 years, there were 130 CV deaths. The analysis showed CV mortality increased with increasing CERT categories from low risk to high risk (log Rank P <.001). Mortality risk was higher in patients with T2D compared with patients without T2D (17.7% vs 9.4%; P <.001).
The investigators reported that CERT categories predicted CV mortality in both patients with T2D (adjusted hazard ratio, 1.65; 95% CI, 1.27-2.15; P <.001) and without T2D (adjusted hazard ratio, 1.41; 95% CI, 1.07-1.85; P =.015).
“CERT predicts cardiovascular mortality in [patients with cardiovascular disease and type 2 diabetes] as well as in those without diabetes,” concluded the researchers.
Leiherer A, Muendlein A, Saely CH, et al. The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes. Presented at: American Diabetes Association 79th Scientific Session; June 7-11, 2019; San Francisco, CA. Poster 416-P.